What is the survival rate with CAR T-cell therapy?
CAR T-cell therapy has shown promising survival outcomes for people with relapsed or refractory multiple myeloma. In a recent study of ciltacabtagene autoleucel (Carvykti), about 33% of participants remained myeloma-free for at least five years after a single infusion.
Show Full Answer
What is the survival rate with CAR T-cell therapy?
CAR T-cell therapy has shown promising survival outcomes for people with relapsed or refractory multiple myeloma. In a recent study of ciltacabtagene autoleucel (Carvykti), about 33% of participants remained myeloma-free for at least five years after a single infusion.
The median overall survival rate in this study was just over five years (60.7 months). This is remarkable compared to the historical median survival of around one year for people with relapsed or refractory myeloma.
Nearly all participants who remained progression-free achieved a stringent complete response, meaning no cancer cells were detected by standard tests. Some showed no signs of disease on imaging scans and had negative minimal residual disease tests five years later.
It's important to note that CAR T-cell therapy can cause serious side effects, including:
- Cytokine release syndrome (CRS)
- Neurological issues (ICANS)
- Infections
- Weakened immune system
Because of these potential risks, CAR T-cell therapy is only performed at specialized centers with close monitoring. Talk with your doctor about whether this treatment might be right for your situation.
March 17
Join
Your Privacy Choices
